Bristol-Myers shares drop; Regenera offers a lifeline to sinking Alcobra

→  The reverberations continue from Bristol-Myers Squibb’s missteps with Opdivo earlier this year. Shares dropped four percent this week as rumors of a potential sale once again began to swirl, Bloomberg reports.  Immuno-oncology and drug combinations are primary focuses for Bristol-Myers Squibb.

→  Regenera shareholders have offered to buy shares of Alcobra for 66.6% of the combined company. Alcobra is running out of options since it hasn’t recovered from the failure of its ADHD drug in September 2014.

→  The big pharma story today: FDA commissioner Scott Gottlieb has asked Endo to pull its controversial opioid Opana ER from the market. A number of lawmakers have been urging Gottlieb to do something about the opioid epidemic, and this would be his first tangible move on that front.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->